Adriforant

DB15027InvestigationalSmall molecule

Adriforant is under investigation in clinical trial NCT00992342 (A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03893787 In Healthy Adult Volunteers).

Mechanism: Pharmacologically active on Histamine H4 receptor
Curator reviewed
Formula / weight: C₁₃H₂₂N₆ · 262.361 g/mol (avg)
Also known as: PF-03893787

Resolves to

Compound

UNIID65H9YE9VUCAS943057-12-3ChEMBLCHEMBL1915540

Structure

InChIKeyISBHYKVAFKTATD-SNVBAGLBSA-NSMILESCN[C@@H]1CCN(C1)C1=CC(NCC2CC2)=NC(N)=N1

Targets

Q9H3N8HRH4

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Adriforant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account